Unlocking Potential: Monovaccine's Rise in the Epstein-Barr Virus Market

The Monovaccine, a groundbreaking immunization against the Epstein-Barr Virus (EBV), has ignited considerable interest in the medical community. As the first of its kind, it promises to revolutionize the treatment landscape for EBV-related diseases.
Mono Vaccine Market size was valued at USD 10.39 Billion in 2024 and is projected to reach USD 18.97 Billion by 2031, growing at a CAGR of 5.74% from 2024 to 2031.